Chemomab Therapeutics Ltd. (NASDAQ: CMMB) is now covered by analysts at Maxim Group. They set a "buy" rating and a $4.00 price target on the stock.
Chemomab Therapeutics Ltd. - American Depositary Shares (CMMB)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
CMMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMMB alerts
High impacting Chemomab Therapeutics Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CMMB
News
- New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic SclerosisGlobeNewswire
- Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]Yahoo! Finance
- Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewswire
- Chemomab Therapeutics Ltd. (NASDAQ: CMMB) had its price target raised by analysts at Maxim Group from $4.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing CholangitisGlobeNewswire
CMMB
Analyst Actions
- 2/20/25 - Maxim Group
CMMB
Sec Filings
- 3/20/25 - Form 6-K
- 3/3/25 - Form 6-K
- 2/19/25 - Form 6-K
- CMMB's page on the SEC website